The group's principle activity is to discover and develop novel small molecule therapeutics in the areas of inflammatory, cardiovascular, and metabolic disorders. The group has also built a promising pipeline that includes back-up and second generation compounds to KC706, small molecule amylin agonists for treatment of obesity/diabetes and a library of several thousand uniquely synthesized, small molecule, allosteric inhibitors that include attractive leads for kinase targets including JNK2, raf and others. The group operates from United States.
